Search

Your search keyword '"Chalmers J.D."' showing total 65 results

Search Constraints

Start Over You searched for: Author "Chalmers J.D." Remove constraint Author: "Chalmers J.D." Database Unpaywall Remove constraint Database: Unpaywall
65 results on '"Chalmers J.D."'

Search Results

1. Diagnostic delay and access to care in bronchiectasis: data from the EMBARC/ELF patient survey

3. Changes in Blood Immune Cell Transcriptomes Associate With Disease Severity, Infection, and Inflammation in Bronchiectasis Patients: Data From the EMBARC-BRIDGE Study

4. Net and Cell Count Differentials Among NTM +/- Bronchiectasis Patients With Cavitary and Non-cavitary Disease

7. Clinical Efficacy of Anti-glycopeptidolipid-core IgA Test for Screening Nontuberculous Mycobacterial Infection in Bronchiectasis: A Multicenter European Study

8. Microbiologic Outcomes From a Randomized, Double-blind Trial of Amikacin Liposome Inhalation Suspension in Adults With Newly Diagnosed or Recurrent Mycobacterium Avium Complex Lung Disease: The ARISE Study

10. Sputum Dipeptidyl Peptidase-1 Activity Associates With Inflammation and Disease Severity in Bronchiectasis: Data From the EMBARC-BRIDGE Study

11. ECFS standards of care on CFTR-related disorders: Identification and care of the disorders

15. A Bispecific Monoclonal Antibody Targeting Psl and PcrV Enhances Bronchiectasis Patient Neutrophil-Mediated Killing of Pseudomonas Aeruginosa

18. The Effect of Inhaled Corticosteroid Withdrawal on the Airway Metagenome and Antimicrobial Resistance: Data From the INCOGNITO Trial

19. Inflammatory Molecular Endotypes of Bronchiectasis Are Related to Microbiome Structure and Diversity: A European Multicenter Cohort Study

20. Prevalence of physical frailty, including risk factors, up to 1 year after hospitalisation for COVID-19 in the UK: a multicentre, longitudinal cohort study

21. SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination

22. ePS3.08 Inhaled powder tobramycin (TIP): cyclical versus continuous treatment: iBEST Study

23. Study Design of a Phase II, Randomized, Double-Blind, Placebo-Controlled Trial of a Novel Cathepsin C Inhibitor BI 1291583 in Patients with Bronchiectasis

25. The Relationship Between Airway Interleukin-1 Beta, Microbial Dysbiosis and Mucus Hyperconcentration in Bronchiectasis: The EMBARC-BRIDGE Study

27. Characterization of Ciliary Function in Bronchiectasis (EMBARC-BRIDGE Study)

28. A Randomized Double-Blind Placebo-Controlled Trial of Dipeptidyl Peptidase-1 Inhibition in Hospitalized Patients with COVID-19: The STOP-COVID19 Trial

29. Transcriptomic Changes in Hospitalised COVID19 Patients Across 29 Days Provide Insight into the Systemic Immune Response and Disease Outcomes: Results from PREDICT-COVID19

31. The Effect of Inhaled Corticosteroid Withdrawal on Inflammation and the Airway Microbiome in COPD: The INCOGNITO Trial

32. Topological Data Analysis (TDA) of Allergic Sensitization in Bronchiectasis and COPD

35. The Seroprevalence and Protective Effect of SARS-COV-2 Antibodies in Scottish Healthcare Workers

36. The Metagenomic ‘Bacteriophagome’ in Bronchiectasis

37. Concurrent Randomized, Double-Blind, Placebo-Controlled Trials to Validate Patient-Reported Outcome (PRO) Instruments and Assess Clinical Benefit of Treatment in Adults with Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium AviumComplex (MAC)

38. Neisseria Species as Novel Respiratory Pathobionts in Bronchiectasis

40. The Neutrophil Granule Protein Olfactomedin-4 Relates to Bronchiectasis Severity and Alters Mucociliary Clearance

45. Systemic Chitotriosidase Activity Is Associated with Airway Aspergillus and Frequent Exacerbations in Bronchiectasis

49. Non-Tuberculous Mycobacteria Testing in Bronchiectasis Patients in Europe: Data from the Embarc Registry

Catalog

Books, media, physical & digital resources